However, longitudinal and interventional studies are now necessary to evaluate NOX2’s predictive role in diabetic complication occurrence, to validate NOX2 as a therapeutic target, and to determine whether NOX inhibitors can reduce the burden of diabetic complications in sub-Saharan Africa, where healthcare resources for managing diabetes are often limited. The gene discussed is CYBB; the disease is diabetes mellitus.